Sexually Transmissible Infections: Outcomes And Interventions.
Funder
National Health and Medical Research Council
Funding Amount
$568,892.00
Summary
Professor Basil Donovan, Head of the Sexual Health Program at UNSW's Kirby Institute, works on a wide range of research endeavours that are aimed at (a) better characterising the causes of sexually transmissible infections (STIs) and their outcomes, (b) determining how they move through populations, and (c) trialing interventions to bring them under control. He has a particular interest in populations that are at increased risk of STIs such as Aboriginal and Torres Strait Islander people, gay me ....Professor Basil Donovan, Head of the Sexual Health Program at UNSW's Kirby Institute, works on a wide range of research endeavours that are aimed at (a) better characterising the causes of sexually transmissible infections (STIs) and their outcomes, (b) determining how they move through populations, and (c) trialing interventions to bring them under control. He has a particular interest in populations that are at increased risk of STIs such as Aboriginal and Torres Strait Islander people, gay men, sex workers, prisoners, and youth.Read moreRead less
Translational Research On Malignant Pleural Effusion And Pleural Infection
Funder
National Health and Medical Research Council
Funding Amount
$487,891.00
Summary
I am a leading researcher in pleural effusions (fluid build-up in the chest) from cancer and infection. I run a multicentre clinical trial team to answer important questions directly relevant to patient care, as well as a lab research group with proven record of discovery new treatment targets. This fellowship will capitalize on platforms I have built and determine best approach to remove effusions, understand etiologic roles of the fluid ultimately to find ways to stop fluid from forming.
I aim to understand the genetics of the epilepsies. Through detailed analysis of different types of epilepsy, and associated features such as intellectual disability and autism, I will describe new epilepsy syndromes, and together with gene discovery, implement novel targeted therapies. This translational program will transform clinical practice by informing diagnosis, prognostic and genetic counseling, and lead to targeted precision therapies to improve outcomes for each patient.
Limiting Tuberculosis Transmission And Improving The Care Of Affected Children
Funder
National Health and Medical Research Council
Funding Amount
$412,419.00
Summary
Tuberculosis (TB) is the biggest infectious disease killer on the planet. Drug-resistant TB poses a particular challenge in the Asia-Pacific region. My research will assist Australia to progress towards domestic TB elimination. It will improve the management of “difficult to treat” cases and help to safeguard the public against ongoing TB transmission. Work in neighbouring countries will help to contain the spread of drug-resistant TB and protect vulnerable young children.
Tackling Key Epidemiological And Basic Scientific Research Issues In Prion Diseases.
Funder
National Health and Medical Research Council
Funding Amount
$401,109.00
Summary
Proposed Practitioner Fellowship research will simultaneously include epidemiological and basic scientific projects, emphasising human prion disease. Epidemiological research will involve large-scale studies to clarify genetic factors that influence susceptibility to developing prion disease, as well as clarify whether Alzheimer disease is transmissible, while basic scientific research will include determining the characteristics of the misfolded prion proteins causing neuronal disease.
Improving Prevention, Tracking And Treatment Of Major Human Bacterial Pathogens
Funder
National Health and Medical Research Council
Funding Amount
$467,961.00
Summary
This research fellowship will lead to a detailed understanding of the mechanisms by which bacteria become resistant to antibiotics and cause diseases, how bacterial pathogens evolve and spread in the Australian community, and will result in new understanding of the optimal treatment of bacterial diseases and identification of compounds for new antibiotic development.
This application will allow me to restructure my work to provide sufficient time to do full justice to the current and planned commitments of our Respiratory Research Group. Our research programme includes the immunopathology of chronic airway diseases; the epidemiology of respiratory disease (TAHS); clinical physiology technology to service these studies; respiratory clinical pharmacology; microbe-host interactions in CF and COPD; and EBM in chronic respiratory disease self-management .
Determinants Of The Outcomes From Infectious Diseases
Funder
National Health and Medical Research Council
Funding Amount
$585,269.00
Summary
This Fellowship will allow Professor Lloyd to continue clinical and laboratory research in two areas: firstly, in relation to prevention of transmission of hepatitis C infection, and scale up of antiviral treatments, particularly amongst prisoners. Secondly, in studies investigating the biological basis of chronic fatigue states following acute infection or cancer treatment, and also in development of effective treatment for chronic fatigue states.
Redefining Antibiotic Dosing To Reduce Bacterial Resistance
Funder
National Health and Medical Research Council
Funding Amount
$474,513.00
Summary
>3000 Australians die every year from severe infections (nearly 3-fold higher in number than our annual road toll). These treatment failures are due to sub-optimal antibiotic dosing from a poor understanding of why concentrations are different in these patients. I will use my laboratory to define what antibiotic concentrations we need to achieve and perform clinical studies with my collaborative network to demonstrate that we can redefine antibiotic dosing to reduce the emergence of superbugs ....>3000 Australians die every year from severe infections (nearly 3-fold higher in number than our annual road toll). These treatment failures are due to sub-optimal antibiotic dosing from a poor understanding of why concentrations are different in these patients. I will use my laboratory to define what antibiotic concentrations we need to achieve and perform clinical studies with my collaborative network to demonstrate that we can redefine antibiotic dosing to reduce the emergence of superbugs.Read moreRead less